BFS
TRIB

Bradley Foster & Sargent’s Trinity Biotech TRIB Stock Holding History

Bradley Foster & Sargent’s Portfolio TRIB Stock Details TRIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-1,935
Closed -$223K – 361
2014
Q2 		$223K Hold
1,935
– – 0.01% 321
2014
Q1 		$234K Hold
1,935
– – 0.01% 315
2013
Q4 		$243K Buy
+1,935
New +$232K 0.01% 318

Other funds holding TRIB

HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return
AAM
ACK Asset Management Greenwich, Connecticut $801M AUM 60.42% 1-Year Est. Return
LSC
Lyon Street Capital Sausalito, California $67M AUM
WA
Whitebox Advisors Minneapolis, Minnesota $8.12B AUM 15.85% 1-Year Est. Return
TAM
THB Asset Management Norwalk, Connecticut $440M AUM 59.59% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
CIP
Chartwell Investment Partners Berywn, Pennsylvania $2.91B AUM 40.48% 1-Year Est. Return
CAM
Cortina Asset Management Milwaukee, Wisconsin $1.62B AUM 15.44% 1-Year Est. Return

Bradley Foster & Sargent's TRIB Position: Q3 2014 in Review

Bradley Foster & Sargent sold out of Trinity Biotech (TRIB) in Q3 2014, closing a stake of 1,935 shares — an estimated $223K sold.

Bradley Foster & Sargent first reported a position in TRIB in Q4 2013 and held it in 3 quarters. The position peaked at $243K in Q4 2013. 95 funds tracked by Wall St. Rank hold TRIB as of Q3 2014.

  • Bradley Foster & Sargent reported no remaining Trinity Biotech position as of Q3 2014 after selling out during the quarter.
  • Bradley Foster & Sargent sold 1,935 Trinity Biotech shares in Q3 2014, an estimated $223K.
  • Bradley Foster & Sargent first reported a position in Trinity Biotech in Q4 2013 and held it in 3 quarters.
  • Bradley Foster & Sargent's Trinity Biotech position peaked at $243K in Q4 2013.
  • 95 funds tracked by Wall St. Rank held Trinity Biotech as of Q3 2014.

Based on Bradley Foster & Sargent's 13F filing for Q3 2014, filed 7 Nov 2014.